#AbbVie #Rinvoq #upadacitinib #giantcellarteritis #oralJAKinhibitor #JAKinhibitor #marketingauthorisation #Januskinaseinhibitor #SELECTGCAtrial #immunology #pharma #pharmaceuticals
zurl.co/ovP8I
zurl.co/ovP8I
AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis - PMLiVE
The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population
pmlive.com
April 16, 2025 at 7:47 AM